Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Ceribell, Inc. ( (CBLL) ) is now available.
On December 9, 2025, Ceribell, Inc. announced that the U.S. Food and Drug Administration granted 510(k) clearance for its proprietary delirium monitoring solution, marking it as the first FDA-cleared device for delirium screening and monitoring. This clearance enhances the Ceribell System’s capabilities as an AI-powered brain monitoring platform, addressing a significant unmet need in delirium monitoring and potentially improving patient outcomes by providing continuous, reliable evaluation. The solution’s validation through rigorous studies underscores its reliability, and the clearance follows a Breakthrough Device Designation received in 2022, highlighting its innovative impact on the healthcare industry.
The most recent analyst rating on (CBLL) stock is a Hold with a $20.50 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.
Spark’s Take on CBLL Stock
According to Spark, TipRanks’ AI Analyst, CBLL is a Neutral.
Ceribell, Inc. demonstrates strong growth potential with significant revenue increases and strategic advancements, such as FDA clearance and supply chain improvements. However, profitability challenges and cash flow issues weigh on the overall score. The technical indicators suggest bullish momentum, but valuation remains a concern due to ongoing losses.
To see Spark’s full report on CBLL stock, click here.
More about Ceribell, Inc.
Ceribell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a point-of-care electroencephalography (EEG) platform designed for rapid diagnosis and continuous monitoring in acute care settings. Ceribell is headquartered in Sunnyvale, California, and its system is FDA-cleared for detecting seizures and delirium in intensive care units and emergency rooms across the U.S.
Average Trading Volume: 347,368
Technical Sentiment Signal: Strong Buy
Current Market Cap: $731.5M
For a thorough assessment of CBLL stock, go to TipRanks’ Stock Analysis page.